Gust C M, Fuller R W
Lilly Research Laboratories, Eli Lilly and Company Lilly Corporate Center, Indianapolis, IN 46285.
Neurosci Lett. 1988 Nov 11;93(2-3):307-11. doi: 10.1016/0304-3940(88)90100-0.
Four daily injections of pergolide, an ergoline dopamine agonist, made male rats tolerant to the corticosterone-elevating effects of an acute injection of pergolide on the fifth day. This tolerance occurred not only to acute treatment with pergolide, but also to other dopamine agonists differing in structure, potency and receptor subtype selectivity. Plasma corticosterone was elevated following administration of opioid or serotonin agonists in both vehicle- and pergolide-pretreated rats. The current findings strengthen the conclusion that tolerance to the acute elevation of corticosterone by pergolide is not due to impairment of pituitary-adrenocortical function but instead to changes in dopamine receptors that initiate the response.
每天注射四次培高利特(一种麦角林多巴胺激动剂),使雄性大鼠对第五天急性注射培高利特所产生的皮质酮升高效应产生耐受。这种耐受不仅发生在培高利特的急性治疗中,也发生在结构、效力和受体亚型选择性不同的其他多巴胺激动剂上。在给予阿片类或5-羟色胺激动剂后,无论是用赋形剂预处理还是用培高利特预处理的大鼠,血浆皮质酮都会升高。目前的研究结果强化了这样一个结论,即对培高利特引起的皮质酮急性升高产生的耐受并非由于垂体-肾上腺皮质功能受损,而是由于引发反应的多巴胺受体发生了变化。